COSMO PHARMACEUTICALS N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 71.6 CHF | -0.69% |
|
+0.28% | +40.67% |
| Apr. 26 | Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024 | CI |
| Apr. 25 | Cosmo Pharmaceuticals Names New CEO, Chairman | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,169 | 1,033 | 1,133 | 1,067 | 1,013 | 1,177 | 1,177 | - |
| Enterprise Value (EV) 1 | 978.1 | 929.6 | 1,088 | 1,014 | 945.3 | 831.9 | 1,067 | 982.5 |
| P/E ratio | -65 x | -42.3 x | -143 x | 49.2 x | 58.9 x | 771 x | 10.6 x | 10.2 x |
| Yield | - | - | - | - | 1.7% | 3.65% | 2.86% | 1.24% |
| Capitalization / Revenue | 17.8 x | 16.5 x | 18.6 x | 16.4 x | 9.92 x | 9.1 x | 4.49 x | 4.86 x |
| EV / Revenue | 14.9 x | 14.9 x | 17.9 x | 15.6 x | 9.26 x | 8.6 x | 4.07 x | 4.06 x |
| EV / EBITDA | -80.6 x | -142 x | 84.1 x | 54.8 x | 22.6 x | 31.4 x | 6.11 x | 6.72 x |
| EV / FCF | -81.1 x | -44.1 x | 123 x | 142 x | 32.9 x | 25 x | 11.4 x | 7.66 x |
| FCF Yield | -1.23% | -2.27% | 0.81% | 0.7% | 3.04% | 4% | 8.78% | 13.1% |
| Price to Book | 2.61 x | 2.6 x | 2.83 x | 2.09 x | 2.2 x | 2.06 x | 2.29 x | 1.95 x |
| Nbr of stocks (in thousands) | 15,002 | 14,623 | 14,463 | 16,838 | 16,384 | 16,053 | 16,053 | - |
| Reference price 2 | 77.95 | 70.64 | 78.34 | 63.36 | 61.81 | 73.32 | 73.32 | 73.32 |
| Announcement Date | 3/29/19 | 4/3/20 | 3/26/21 | 3/23/22 | 3/23/23 | 3/20/24 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 65.62 | 62.5 | 60.95 | 65.07 | 102.1 | 96.72 | 261.9 | 241.9 |
| EBITDA 1 | -12.14 | -6.552 | 12.94 | 18.5 | 41.91 | 26.49 | 174.6 | 146.3 |
| EBIT 1 | -16.62 | -12.31 | 6.905 | 11.1 | 28.06 | 12.23 | 158.1 | 128.1 |
| Operating Margin | -25.33% | -19.69% | 11.33% | 17.06% | 27.48% | 12.64% | 60.38% | 52.94% |
| Earnings before Tax (EBT) 1 | -17.46 | -21.3 | -6.931 | 24 | 24.47 | 7.611 | 162.5 | 149.9 |
| Net income 1 | -18.06 | -24.49 | -7.901 | 21.67 | 17.22 | 1.147 | 111 | 102.1 |
| Net margin | -27.52% | -39.19% | -12.96% | 33.31% | 16.87% | 1.19% | 42.38% | 42.19% |
| EPS 2 | -1.200 | -1.669 | -0.5460 | 1.287 | 1.049 | 0.0710 | 6.895 | 7.153 |
| Free Cash Flow 1 | -12.06 | -21.09 | 8.865 | 7.124 | 28.71 | 33.31 | 93.7 | 128.3 |
| FCF margin | -18.38% | -33.75% | 14.54% | 10.95% | 28.12% | 34.44% | 35.78% | 53.01% |
| FCF Conversion (EBITDA) | - | - | 68.51% | 38.51% | 68.5% | 125.76% | 53.65% | 87.66% |
| FCF Conversion (Net income) | - | - | - | 32.87% | 166.68% | 2,904.1% | 84.41% | 125.66% |
| Dividend per Share 2 | - | - | - | - | 1.050 | 2.000 | 2.100 | 0.9128 |
| Announcement Date | 3/29/19 | 4/3/20 | 3/26/21 | 3/23/22 | 3/23/23 | 3/20/24 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S1 | 2019 S2 | 2020 S1 | 2021 S1 | 2022 S1 | 2022 S2 | 2023 S1 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 21.51 | 40.99 | 25.88 | 28.42 | 41.51 | 60.58 | 43.66 | 131.3 | 35.8 | 142.5 | 42.8 | 113.9 |
| EBITDA | - | 8.041 | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -17.2 | 4.894 | 2.662 | 0.008 | 8.108 | 19.95 | 7.123 | 108.3 | 11.1 | 94.6 | 15.44 | 66.9 |
| Operating Margin | -79.98% | 11.94% | 10.28% | 0.03% | 19.53% | 32.93% | 16.31% | 82.49% | 30.99% | 66.39% | 36.07% | 58.74% |
| Earnings before Tax (EBT) | -22.62 | 1.315 | -5.331 | -4.667 | 9.089 | 15.38 | 3.673 | - | - | 95 | - | 67.5 |
| Net income | -20.78 | -3.712 | -3.015 | -5.741 | 7.896 | 9.329 | 1.486 | - | - | 68.4 | - | 48.6 |
| Net margin | -96.63% | -9.06% | -11.65% | -20.2% | 19.02% | 15.4% | 3.4% | - | - | 48% | - | 42.67% |
| EPS | -1.407 | -0.2620 | -0.2080 | -0.3990 | 0.4760 | 0.5730 | 0.0920 | - | - | 4.260 | - | 3.020 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 7/30/19 | 4/3/20 | 7/30/20 | 7/30/21 | 7/28/22 | 3/23/23 | 7/26/23 | - | - | - | - | - |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 191 | 103 | 44.7 | 52.3 | 67.4 | 48.4 | 110 | 195 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -12.1 | -21.1 | 8.87 | 7.12 | 28.7 | 33.3 | 93.7 | 128 |
| ROE (net income / shareholders' equity) | -3.95% | -5.83% | - | - | 3.58% | 0.26% | 22.1% | 18.8% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 29.90 | 27.10 | 27.70 | 30.20 | 28.10 | 26.60 | 32.00 | 37.50 |
| Cash Flow per Share 2 | -0.6800 | - | 0.9000 | 0.7500 | 2.020 | 2.090 | 5.780 | 2.920 |
| Capex 1 | 1.9 | 2.25 | 4.12 | - | 4.52 | 3.35 | 9.9 | 6.89 |
| Capex / Sales | 2.89% | 3.59% | 6.76% | - | 4.42% | 3.46% | 3.78% | 2.85% |
| Announcement Date | 3/29/19 | 4/3/20 | 3/26/21 | 3/23/22 | 3/23/23 | 3/20/24 | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
73.32
EUR
Average target price
95.38
EUR
Spread / Average Target
+30.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.67% | 1.26B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- COPN Stock
- Financials Cosmo Pharmaceuticals N.V.
